$EDIT

Editas Medicine, Inc.

CIK:0001650664|SEC Filings

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Collaboration and other research and development revenues	$ 11,890	$ 3,578	$ 14,721	$ 8,236
Operating expenses:
Research and development	20,180	16,181	37,780	42,774
General and administrative	11,603	12,859	21,837	26,234
Restructuring and impairment charges	(1,339)	26,082	(1,339)	66,935
Total operating expenses	30,444	55,122	58,278	135,943
Operating loss	(18,554)	(51,544)	(43,557)	(127,707)
Other income (expense), net:
Interest expense related to sale of future revenues	(1,061)	(2,020)	(2,133)	(4,236)
Interest income, net	1,368	2,087	2,574	4,803
Other income (expense), net	17	(1,758)	(96)	(2,183)
Total other income (expense), net	324	(1,691)	345	(1,616)
Net loss	$ (18,230)	$ (53,235)	$ (43,212)	$ (129,323)
Net loss per share, basic (in dollars per share)	$ (0.15)	$ (0.63)	$ (0.40)	$ (1.54)
Net loss per share, diluted (in dollars per share)	$ (0.15)	$ (0.63)	$ (0.40)	$ (1.54)
Weighted-average common shares outstanding, basic (in shares)	119,294,615	84,412,200	108,646,137	83,737,382
Weighted-average common shares outstanding, diluted (in shares)	119,294,615	84,412,200	108,646,137	83,737,382

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flow from operating activities
Net loss	$ (43,212)	$ (129,323)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	4,295	5,643
Depreciation	899	3,751
Loss on disposal of fixed assets	111	2,193
Net accretion of discounts on marketable securities	(142)	(840)
Interest related to sale of future revenues	2,133	4,236
Impairment of held for sale assets	0	3,724
Other non-cash items	(17)	(390)
Changes in operating assets and liabilities:
Accounts receivable	12,451	15,678
Prepaid expenses and other current assets	(1,623)	(418)
Right-of-use assets	2,242	8,694
Other non-current assets	0	1,025
Accounts payable	1,669	1,231
Accrued expenses	(15,397)	2,271
Accrued interest on sale of future revenues	(5,000)	(2,128)
Deferred revenue	(8,194)	(6,221)
Operating lease liabilities	(2,442)	(9,048)
Other non-current liabilities	(402)	1,911
Net cash used in operating activities	(52,629)	(98,011)
Cash flow from investing activities
Purchases of property and equipment	(198)	(114)
Proceeds from the sale of equipment	156	151
Purchases of marketable securities	(29,694)	0
Proceeds from maturities of marketable securities	0	99,000
Net cash provided by (used in) investing activities	(29,736)	99,037
Cash flow from financing activities
Proceeds from offering of common stock, net of issuance costs	117,499	8,619
Repayment on sale of future revenues	0	(2,872)
Proceeds from exercise of stock options	36	0
Proceeds from issuance of common stock under employee stock purchase plan	0	228
Net cash provided by financing activities	117,535	5,975
Net increase (decrease) in cash, cash equivalents, and restricted cash	35,170	7,001
Cash, cash equivalents, and restricted cash, beginning of period	149,315	135,418
Cash, cash equivalents, and restricted cash, end of period	184,485	142,419
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]
Cash and cash equivalents, end of period	181,815	138,542
Restricted cash	2,670	3,877
Cash, cash equivalents, and restricted cash, end of period	184,485	142,419
Supplemental disclosure of cash and non-cash activities:
Offering expenses included in accounts payable and accrued expenses	619	0
Cash paid for interest	5,000	2,128
Cash paid in connection with operating lease liabilities	4,011	11,048
Remeasurement of operating lease liabilities and right-of-use assets due to lease modification	793	766
Non-cash termination of right-of-use asset	$ 0	$ 4,849

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 181,815	$ 146,645
Marketable securities	29,830	0
Accounts receivable	2,725	15,176
Prepaid expenses and other current assets	3,697	2,074
Total current assets	218,067	163,895
Property and equipment, net	2,574	3,542
Right-of-use assets	13,747	16,121
Restricted cash and other non-current assets	2,976	2,976
Total assets	237,364	186,534
Current liabilities:
Accounts payable	4,741	2,605
Accrued expenses	17,365	32,610
Liability for sale of future revenues, current	7,500	5,000
Deferred revenue, current	32,315	0
Operating lease liabilities, current	6,513	6,031
Total current liabilities	68,434	46,246
Operating lease liabilities, net of current portion	8,998	12,071
Liability for sale of future revenues, net of current portion	48,238	53,605
Deferred revenue, net of current portion	4,000	44,509
Other non-current liabilities	2,413	2,815
Total liabilities	132,083	159,246
Commitments and contingencies (Note 7)
Stockholders’ equity
Preferred stock, $0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.0001 par value per share: 390,000,000 shares authorized; 153,530,898 and 97,866,996 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	15	10
Additional paid-in capital	1,776,987	1,655,781
Accumulated other comprehensive income (loss)	(6)	0
Accumulated deficit	(1,671,715)	(1,628,503)
Total stockholders’ equity	105,281	27,288
Total liabilities and stockholders’ equity	$ 237,364	$ 186,534